Investigational neuropeptide (cognitive / nootropic — sleep EEG slow-wave modulation, stress / HPA axis, non-opioid antinociception, RECEPTOR UNIDENTIFIED) Limited Human Data

DSIP

Also Known As: Delta Sleep-Inducing Peptide, δ-Sleep-Inducing Peptide, Delta-sleep-inducing nonapeptide, WAGGDASGE peptide, H-Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu-OH (free acid)

DSIP — Delta Sleep-Inducing Peptide — is a 9-amino-acid nonapeptide with the sequence H-Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu-OH (one-letter WAGGDASGE; CAS 62568-57-4; PubChem CID 68816; molecular formula C₃₅H₄₈N₁₀O₁₅; molecular weight ≈ 848.81 Da). It was isolated in 1977 by Guido A. Schoenenberger and Marcel Monnier at the University of Basel from the cerebral venous blood of rabbits subjected to hypnogenic electrical stimulation of the intralaminar thalamic area — the group named the peptide for its reported property of enhancing EEG delta (slow-wave) activity (Schoenenberger & Monnier 1977 PNAS PMID 265572). #1 EDITORIAL READER GUARDRAIL — RECEPTOR UNIDENTIFIED: after more than four decades of research (1977–2026), NO DSIP receptor has been cloned, deorphanised, or pharmacologically validated. The DSIP precursor gene has not been definitively identified. Kovalzon & Strekalova summarised the field in 2006 in the Journal of Neurochemistry (PMID 16539679) as "a still unresolved riddle" — DSIP is one of the most-studied neuropeptides without a defined molecular target. Mechanism statements are therefore pleiotropic and partly speculative; every claim is hedged as "studies report" and observed in research settings. SCHOENENBERGER- / RUSSIAN-LINEAGE DOMINANCE CAVEAT: the DSIP literature is overwhelmingly produced by (i) the original Basel group (Schoenenberger, Monnier; 1970s–1990s) and (ii) Russian / Soviet successor groups (Mikhaleva, Prudchenko, Khvatova, Kovalzon, Strekalova, Ivanov, Tukhovskaya). Independent Western replication is sparse. This is a single-research-lineage-dominance pattern that runs directly parallel to Khavinson / Epitalon, Goldspink / PEG-MGF, and Harding / Dihexa. REGISTRY GAP — important: a systematic ClinicalTrials.gov v2 API audit on 2 May 2026 for "delta sleep inducing peptide", "DSIP", and "WAGGDASGE" returned ZERO trials with DSIP as the studied intervention; 49 years post-discovery, there is no FDAAA-registered DSIP intervention trial. Regarding sleep-medication framing: DSIP does NOT bind directly to the GABA-A receptor or the benzodiazepine binding site and is NOT a classical sedative-hypnotic in the pharmacological sense — vendor and forum framings as a "natural sleep aid" or "benzodiazepine alternative" are scientifically UNSUPPORTED. Limited human data — preclinical reports and small uncontrolled observations. Research use only.

Identity & Chemistry

Chemical structure of Delta Sleep-Inducing Peptide (DSIP), a 9-residue free-acid nonapeptide with sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (one-letter WAGGDASGE).
Image credit: Wikimedia Commons / Vortioxetine (own work, uploaded 12 December 2020). Source: Wikipedia article on Delta-sleep-inducing peptide. · Public Domain
Amino Acid Sequence
H-Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu-OH (one-letter WAGGDASGE; 9 residues; free-acid C-terminus). The free-acid 9-residue form is the canonical chemical entity described on this page (PubChem CID 68816, CAS 62568-57-4, formula C₃₅H₄₈N₁₀O₁₅). Two related but chemically DISTINCT forms must not be conflated: phosphorylated DSIP (P-DSIP, Ser-7 phosphorylated, C₃₅H₄₉N₁₀O₁₈P, PubChem CID 172600) and longer "DSIP-immunoreactive" brain peptides (e.g. the 77-residue porcine leucine-zipper peptide recognised by anti-DSIP antiserum, PMID 8375381). Vendor catalogues sometimes fail to disambiguate; this page anchors explicitly to free-acid 9-residue WAGGDASGE.
Molecular Formula
C₃₅H₄₈N₁₀O₁₅
Molecular Weight
~848.81 Da (PubChem average MW reported as 848.8 g·mol⁻¹; literature variance 848.81–848.82 Da reflects rounding only). The Ser-7 phosphorylated form (C₃₅H₄₉N₁₀O₁₈P, CID 172600) carries an additional phosphate group and is a SEPARATE chemical entity at ≈ 928.79 Da — it is not interchangeable with the canonical free-acid 9-residue form described here.
CAS Number
62568-57-4 (free-acid 9-residue WAGGDASGE; verified across Sigma-Aldrich D4072, Biosynth PDS-4054, Phoenix Pharmaceuticals, and Wikipedia)
PubChem CID
68816
DrugBank ID
DB12707 (entry expected to exist per briefing; direct DrugBank fetch returned 403 in the 2026-05-02 audit and is recorded as "verify at indexing" rather than asserted)
IUPAC Name
L-tryptophyl-L-alanyl-glycyl-glycyl-L-α-aspartyl-L-alanyl-L-seryl-glycyl-L-glutamic acid (long systematic peptide IUPAC string; the free-acid 9-residue WAGGDASGE form indexed at PubChem CID 68816).
Solubility
Soluble in water and dilute aqueous buffers; the peptide is amphiphilic and dominated by polar acidic and neutral residues (~850 Da). Quantitative aqueous solubility data are not publicly disclosed at PubChem CID 68816. Reconstitution typically performed in sterile bacteriostatic or distilled water for laboratory use. For research use only.
Storage
Lyophilised powder: store at −20 °C, desiccated, protected from light. Reconstituted peptide: short-term use at 2–8 °C; longer-term storage at −20 °C in single-use aliquots to avoid freeze-thaw cycles. The literature reports a short plasma half-life (on the order of 15 minutes in vitro) due to a specific aminopeptidase-like enzymatic degradation. Vendor / supplier certificate of analysis governs; for research use only.

Mechanism of Action

Studies report pleiotropic effects of DSIP, BUT no DSIP receptor has been identified after 40+ years of research. Reported actions include (i) modulation of sleep architecture / EEG slow-wave activity (original Schoenenberger finding 1977 in rabbits), (ii) dampening of stress-induced cortisol responses, (iii) non-opioid antinociception (naloxone-INSENSITIVE, Yehuda & Carasso 1987), (iv) protection against oxidative stress in preclinical hypoxia models, and (v) indirect modulation of GABAergic and NMDA currents. Important: DSIP does NOT bind directly to GABA-A or the benzodiazepine binding site — it is NOT a classical sedative. Observed in research settings; mechanism pending receptor-level validation.

The mechanistic narrative around DSIP is shaped by the unresolved receptor problem. Schoenenberger & Monnier isolated DSIP in 1977 by dialysis of cerebral venous blood from rabbits subjected to electrical stimulation of the intralaminar thalamic area, and named the peptide for its reported EEG delta-wave-enhancing property. In the five decades since, no DSIP receptor has been cloned; there is no pharmacologically validated molecular binding site. Kovalzon & Strekalova (2006, J Neurochem PMID 16539679) explicitly characterise DSIP as "a still unresolved riddle" and question whether DSIP is a true endogenous sleep factor at all. The reported actions are pleiotropic: Yehuda & Carasso (1987 Int J Neurosci PMID 3679693) reported naloxone-insensitive antinociception in rats — i.e. NOT a classical opioid mechanism. Khvatova et al. (2003 Peptides PMID 12668217) reported mitochondrial protection against hypoxia-induced respiratory loss at 120 µg/kg DSIP. Tukhovskaya et al. (2021 Molecules PMID 34500605) reported improved motor function (rotarod) and reduced infarct size in a focal stroke model in SD rats; this replication, however, comes from the Mikhaleva / Russian-group lineage rather than Western independent replication. In human data, a small (n=24) RANDOMISED PILOT exists during isoflurane anaesthesia — Pomfrett et al. (2009 Eur J Anaesthesiol PMID 19142086) reported dose-dependent changes in bispectral index (BIS), EEG, and heart rate variability at DSIP 25 / 50 / 100 nmol/kg versus saline. This is NOT a sleep RCT; it is an anaesthesia-adjunct pilot. IMPORTANT EDITORIAL SCOPING: DSIP is NOT a classical sedative-hypnotic, does NOT bind to GABA-A or the benzodiazepine binding site, and CANNOT be framed as a "benzodiazepine alternative" — vendor and forum narratives of that type are scientifically UNSUPPORTED. Mechanism statements here are intentionally hedged — studies report, observed in research settings — and never framed as established human pharmacology. Research use only.

Molecular Targets

  • Receptor UNIDENTIFIED — no DSIP receptor has been cloned, deorphanised, or pharmacologically validated in 40+ years (Kovalzon & Strekalova 2006, J Neurochem, PMID 16539679 — "still unresolved riddle"); the DSIP precursor gene has not been definitively identified
  • EEG slow-wave activity — original findings of Schoenenberger & Monnier 1977 (PNAS, PMID 265572): intraventricular DSIP infusion enhanced EEG delta-wave activity in rabbits; modern human polysomnography RCTs are ABSENT and replication in Western literature is sparse
  • HPA axis / stress cortisol — Russian-lineage preclinical reports (Khvatova, Yehuda, Mikhaleva lineages) report dampening of stress-induced cortisol / corticosterone responses
  • Antinociception (NON-OPIOID) — Yehuda & Carasso 1987 (Int J Neurosci, PMID 3679693): DSIP raised hot-plate pain thresholds in rats during light AND dark periods; analgesia was NOT blocked by naloxone — implying mechanism independent of classical opioid receptor signalling
  • Mitochondrial / oxidative-stress protection — Khvatova et al. 2003 (Peptides, PMID 12668217): DSIP pretreatment 120 µg/kg fully prevented hypoxia-induced reduction of respiratory activity in rat brain mitochondria
  • GABAergic and NMDA modulation (INDIRECT) — slice-preparation work suggests enhancement of some GABA-activated currents and modulation of NMDA-mediated responses; CRITICAL: DSIP does NOT bind directly to the GABA-A receptor or the benzodiazepine binding site and is NOT a classical sedative-hypnotic

Signaling Pathways

  • Proposed presynaptic action on thalamocortical circuits modulating EEG delta-wave activity — based on the original Schoenenberger hypothesis; the molecular target remains unidentified (Kovalzon 2006)
  • Proposed HPA-axis dampening with reduction of cortisol / corticosterone peak responses — preclinical reports; no human RCT confirms
  • Antinociception via NON-OPIOID, naloxone-insensitive pathway — Yehuda & Carasso 1987; contradicts classical μ / δ / κ opioid receptor mechanisms
  • Mitochondrial protection via elevation of phosphorylating respiration V₃ and respiratory control ratio (RCR) under hypoxia — Khvatova 2003; molecular-level mechanism unclear
  • NOT a classical sedative-hypnotic profile — DSIP does NOT bind directly to GABA-A or the benzodiazepine binding site; vendor / forum framing as "benzodiazepine alternative" is UNSUPPORTED

Research Applications

The published evidence base is predominantly preclinical (rabbit / rat / mouse in vivo + isolated mitochondria) plus one small human anaesthesia-adjunct pilot (n=24). The Schoenenberger / Basel original lineage (1977–1990s) established the DSIP concept; Russian successor groups (Khvatova, Mikhaleva, Tukhovskaya, Ivanov) provided mitochondrial, stress and stroke data. The Pomfrett / Manchester lineage (2001 review, 2009 pilot) provided the only peer-reviewed human pilot dataset. ClinicalTrials.gov v2 API audit on 2 May 2026 for "delta sleep inducing peptide", "DSIP", "WAGGDASGE": ZERO trials with DSIP as the intervention; the only matches NCT01116401 (leuprolide hot-flash study) and NCT03664531 (gluten / wheat IBS crossover) are keyword-match false positives and are NEVER cited as DSIP trials. Observed in research settings.

EEG slow-wave / sleep — in vivo, rabbit, intraventricular infusion

in vivo

Studies report that intraventricular DSIP infusion enhanced EEG delta (slow-wave) activity in rabbits — the observation that gave DSIP its name. Double-blind tests in n=58 rabbits. Subsequent human polysomnography replication attempts produced mixed and largely inconclusive results; modern RCTs are absent.

— Schoenenberger & Monnier 1977, PNAS USA 74(3):1282-1286 (PMID 265572)

Anaesthesia adjunct (human pilot) — small randomised pilot, n=24, isoflurane

Phase I

Studies report that DSIP (25 / 50 / 100 nmol/kg) dose-dependently altered bispectral index (BIS), EEG, and heart rate variability during isoflurane anaesthesia versus saline. NOT a sleep RCT; an anaesthesia-adjunct pilot. No major adverse events at the doses tested, but the study was not designed or powered for safety endpoints.

— Pomfrett et al. 2009, Eur J Anaesthesiol 26(2):128-134 (PMID 19142086)

Antinociception (NON-OPIOID) — in vivo, rat, hot-plate, naloxone challenge

in vivo

Studies report higher pain thresholds vs control in BOTH light and dark periods; CRITICAL: the analgesia was NOT reversed by naloxone — implying mechanism independent of the classical opioid receptor pathway.

— Yehuda & Carasso 1987, Int J Neurosci 37(1-2):77-83 (PMID 3679693)

Oxidative stress / hypoxia protection — in vivo, rat, isolated brain mitochondria

in vivo

Studies report that DSIP pretreatment 120 µg/kg increased phosphorylating respiration V₃, improved respiratory control ratio, and fully prevented hypoxia-induced respiratory decrement in rat brain mitochondria.

— Khvatova et al. 2003, Peptides 24(2):307-311 (PMID 12668217)

Focal stroke recovery — in vivo, SD rat, 21-day rotarod

in vivo

Studies report, in a focal stroke SD-rat model, modest reduction of infarct size and significantly accelerated motor-function recovery on the rotarod test. Replication comes from the Mikhaleva / Russian-group lineage.

— Tukhovskaya et al. 2021, Molecules 26(17):5173 (PMID 34500605)

Mechanism / receptor status — review

preclinical

Review concludes that the DSIP gene, precursor and receptor remain unidentified, and questions whether DSIP is a true endogenous sleep factor. Critical editorial anchor for the receptor-UNIDENTIFIED caveat.

— Kovalzon & Strekalova 2006, J Neurochem 97(2):303-309 (PMID 16539679)

Clinical overview — anaesthesia application

observational

Review article describes the DSIP concept in the context of anaesthesiological applications; identifies the gap between existing small pilot studies and the absence of large registered RCTs.

— Pollard & Pomfrett 2001, Eur J Anaesthesiol 18(7):419-422

Clinical Status

Regulatory Status
DSIP is NOT approved — by the FDA, EMA, MHRA, PMDA, Health Canada, TGA, NMPA or ANVISA — and does not appear in any Western or international pharmacopoeia as an active substance. There is NO registered Phase 2 or Phase 3 RCT in any major regulatory jurisdiction. A systematic ClinicalTrials.gov v2 API query on 2 May 2026 for "delta sleep inducing peptide", "DSIP" and "WAGGDASGE" returned ZERO trials with DSIP as the studied intervention. CRITICAL EDITORIAL SCOPING — FORBIDDEN-NCT LIST: NCT01116401 ("Impact of Experimentally Induced Hot Flashes on Sleep and Mood Disturbance" — leuprolide intervention; "sleep" matched as keyword) and NCT03664531 ("Crossover Trial of Purified Gluten and Whole Wheat..." — gluten / wheat intervention; "inducing" matched as keyword) are keyword-match false positives and do NOT study DSIP. These NCT IDs must NEVER be cited as DSIP trials and are explicitly EXCLUDED from this page. The Russian preparation "Deltaran", which contains DSIP, is described in Western literature as uncontrolled / non-blinded clinical observation in opioid- and alcohol-withdrawal, paediatric oncology supportive care, and narcolepsy / epilepsy / depression reports — these reports are NOT FDAAA / ICH-GCP-grade RCTs, are of low methodological quality, and should NOT be cited as efficacy evidence. Anti-doping (WADA): DSIP is NOT explicitly named on the 2026 WADA Prohibited List; it does NOT fall under S2 (peptide hormones, growth factors, related substances and mimetics) because DSIP is not a hormone analogue; through the WADA S0 residual clause (non-approved substances with no current approval by any governmental regulatory health authority for human therapeutic use) DSIP is prohibited at all times for athletes under WADA jurisdiction in both in-competition and out-of-competition use. Vendor-market caveat: DSIP is widely sold by research-peptide vendors (Biosynth, Phoenix, ProSpec, CPC Scientific, Sigma-Aldrich D4072 reagent, plus a long tail of grey-market sleep / longevity vendors) and discussed on sleep-hacking, nootropic, and longevity forums as a "natural sleep aid" or "benzodiazepine alternative" — both framings are scientifically UNSUPPORTED and are REJECTED on this page.
Show more
Highest Trial Phase
Highest published phase: small human Phase I pilot (anaesthesia-adjunct, n=24 women under isoflurane; Pomfrett 2009 PMID 19142086) — NOT a sleep RCT, NO Phase 2/3 RCT registered or published. Preclinical majority of the evidence base (rabbit, rat, mouse). ClinicalTrials.gov v2 API audit result 2026-05-02: ZERO hits for "delta sleep inducing peptide" as intervention; ZERO hits for "DSIP" as intervention; ZERO hits for "WAGGDASGE".
Show more
Sponsor
Academic research lineage: Guido A. Schoenenberger and Marcel Monnier (University of Basel, original isolation 1977 and Basel follow-on work into the 1980s–90s); Pomfrett, Pollard et al. (University of Manchester, 2001 review and 2009 anaesthesia pilot); Russian successor lineage: Mikhaleva, Prudchenko, Khvatova, Kovalzon, Strekalova, Ivanov, Tukhovskaya (Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, RAS, Moscow, and associated Russian groups, 1980s–2021); Yehuda & Carasso (Bar-Ilan University, 1987 antinociception work). NO commercial development programme for DSIP is identifiable at audit date; "Deltaran" is a Russian preparation containing DSIP described in uncontrolled clinical observations rather than registered RCTs.
Show more

Safety Profile

Observed in research settings

Limited human data — preclinical reports and small uncontrolled human observations. No modern, FDAAA-registered safety trial of DSIP exists. Statements about human safety are therefore OBSERVATIONAL AND UNCERTAIN. Observed in research settings; for research use only.

Adverse Events Reported in Studies

  • Pomfrett 2009 anaesthesia pilot (n=24): no major adverse events were reported at DSIP doses up to 100 nmol/kg during isoflurane anaesthesia, but the study was NOT designed or powered for safety endpoints
  • Older uncontrolled Soviet / Russian reports describe DSIP as generally well tolerated by short-term parenteral administration, with no consistent pattern of severe adverse events — these reports are confounded by the absence of placebo controls, blinding, and standardised adverse-event capture
  • Preclinical rodent toxicology in the published literature is limited; long-term toxicology and reproductive toxicology data have not been comprehensively reported in peer-reviewed Western literature
  • DSIP is reported in the literature to cross the blood–brain barrier, which is relevant to off-target CNS exposure for non-approved compounds
  • Human studies: ZERO — no systematically captured adverse events from modern human RCTs exist because zero registered Phase 2/3 trials exist at audit date 2026-05-02

Serious Adverse Events

  • Human data gap: ZERO independent long-term pharmacovigilance dataset for DSIP — multi-month or multi-year human safety data have not been published. Safety statements should be tagged exclusively as "limited human data — preclinical reports and small uncontrolled observations only"
  • Pregnancy / lactation: unknown; no data
  • Vendor-market caveat: DSIP is widely sold by research-peptide vendors and prominent on sleep-hacking, nootropic, longevity, and biohacker forums as a "natural sleep aid" or "benzodiazepine alternative" — both framings are scientifically UNSUPPORTED and are REJECTED on this page. Triscience keeps DSIP copy strictly research-only, not for human consumption
  • Anti-doping: WADA Class S0 (Non-Approved Substances) by the residual clause — default classification for non-approved peptides without current regulatory authorisation; NOT S2, because DSIP is not a hormone analogue
  • Adverse-event registry signals: none located at audit date

References

  1. Schoenenberger GA, Monnier M Characterization of a delta-electroencephalogram (-sleep)-inducing peptide Proceedings of the National Academy of Sciences USA 1977;74(3):1282-1286. 1977 .

    DOI: 10.1073/pnas.74.3.1282 PMID: 265572 View Source

  2. Pollard BJ, Pomfrett CJD Delta sleep-inducing peptide European Journal of Anaesthesiology 2001;18(7):419-422. 2001 .

    View Source

  3. Pomfrett CJD, Dolling S, Anders NRK, Glover DG, Bryan A, Pollard BJ Delta sleep-inducing peptide alters bispectral index, the electroencephalogram and heart rate variability when used as an adjunct to isoflurane anaesthesia European Journal of Anaesthesiology 2009;26(2):128-134. 2009 .

    DOI: 10.1097/EJA.0b013e32831c8644 PMID: 19142086 View Source

  4. Khvatova EM, Samartzev VN, Zagoskin PP, Prudchenko IA, Mikhaleva II Delta sleep inducing peptide (DSIP): effect on respiration activity in rat brain mitochondria and stress protective potency under experimental hypoxia Peptides 2003;24(2):307-311. 2003 .

    DOI: 10.1016/s0196-9781(03)00040-8 PMID: 12668217 View Source

  5. Yehuda S, Carasso RL The effects of DSIP on pain threshold during light and dark periods in rats are not naloxone-sensitive International Journal of Neuroscience 1987;37(1-2):77-83. 1987 .

    PMID: 3679693 View Source

  6. Kovalzon VM, Strekalova TV Delta sleep-inducing peptide (DSIP): a still unresolved riddle Journal of Neurochemistry 2006;97(2):303-309. 2006 .

    DOI: 10.1111/j.1471-4159.2006.03693.x PMID: 16539679 View Source

  7. Tukhovskaya EA, Ismailova AM, Shaykhutdinova ER, Slashcheva GA, Prudchenko IA, Mikhaleva II, Khokhlova ON, Murashev AN, Ivanov VT Delta Sleep-Inducing Peptide Recovers Motor Function in SD Rats after Focal Stroke Molecules 2021;26(17):5173. 2021 .

    DOI: 10.3390/molecules26175173 PMID: 34500605 View Source

Frequently Asked Questions

What is DSIP?
DSIP (Delta Sleep-Inducing Peptide) is a 9-amino-acid nonapeptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (one-letter WAGGDASGE; CAS 62568-57-4; PubChem CID 68816). It was isolated in 1977 by Guido A. Schoenenberger and Marcel Monnier at the University of Basel from the cerebral venous blood of rabbits, and named for its reported property of enhancing EEG delta (slow-wave) activity. DSIP is an investigational research peptide, NOT approved for human therapeutic use, and its receptor remains UNIDENTIFIED after more than 40 years.
Does DSIP bind to a known receptor?
No. After more than 40 years since DSIP's 1977 isolation, NO DSIP receptor has been identified, cloned, or pharmacologically validated. The DSIP precursor gene has not been definitively characterised. A 2006 Journal of Neurochemistry review (Kovalzon & Strekalova, PMID 16539679) explicitly described DSIP as "a still unresolved riddle" — DSIP is one of the most-studied neuropeptides without a defined molecular target.
Is DSIP FDA approved?
No. DSIP is NOT approved by the FDA, the EMA, or any other major regulatory authority for any indication. It is an investigational research peptide with no marketing authorisation. As of the ClinicalTrials.gov v2 audit on 2 May 2026, there are ZERO registered trials with DSIP as the studied intervention.
Has DSIP been tested in modern Phase 2/3 RCTs?
No. There are NO modern, FDAAA-registered Phase 2 or Phase 3 randomised controlled trials of DSIP. The only registered human study is a small (n=24) Phase I anaesthesia-adjunct pilot by Pomfrett and colleagues published in 2009 (PMID 19142086), which examined bispectral index and EEG changes during isoflurane anaesthesia — NOT a sleep RCT. Older Soviet / Russian human reports are uncontrolled clinical observations, NOT RCTs.
Is DSIP a benzodiazepine alternative?
No. DSIP is sometimes marketed by research-peptide vendors and discussed on forums as a "benzodiazepine alternative" or "natural sleep aid", but DSIP does NOT bind directly to the GABA-A receptor or the benzodiazepine binding site and is NOT a classical sedative-hypnotic in the pharmacological sense. It has no validated receptor, no regulatory approval, and no robust modern human efficacy data for sleep induction. The benzodiazepine-alternative framing is scientifically UNSUPPORTED.
Who discovered DSIP?
DSIP was isolated and characterised in 1977 by Guido A. Schoenenberger and Marcel Monnier and colleagues at the University of Basel, Switzerland. Their original paper appeared in the Proceedings of the National Academy of Sciences USA (PMID 265572). The peptide was extracted from the cerebral venous blood of rabbits subjected to hypnogenic electrical stimulation of the intralaminar thalamic area and named for its reported EEG slow-wave (delta) enhancing property.
Why is DSIP classified as "Reduced" rather than "Full" on this site?
Although DSIP meets the numeric threshold of ≥5 peer-reviewed primary references, the Full classification is reserved for compounds with (i) a defined receptor / mechanism, (ii) modern independent replication beyond a single research lineage, and (iii) at least one registered Phase 2/3 RCT. DSIP fails all three: receptor unidentified, literature dominated by the Basel Schoenenberger lineage and Russian successor groups, ZERO registered RCTs. Reduced is therefore the appropriate tier.

Related Peptides

Selank

≥98%

Synthetic Heptapeptide (TKPRPGP, Cognitive-Nootropic Class — Investigational Anxiolytic)

Synthetic heptapeptide Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP), registered in Russia in 2009 as an intranasal 0.15% spray for anxiety disorders. No Western Phase I/II/III RCTs exist; the published evidence is dominated by the Myasoedov / Ashmarin RAMS lineage. Research use only; not approved by FDA or EMA.

View Details

Semax

≥98%

Synthetic Heptapeptide (MEHFPGP, Cognitive-Nootropic Class — Neuroprotective Research Peptide)

Synthetic heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP) approved in Russia for acute ischaemic stroke (1% intranasal) and cognitive indications (0.1% intranasal) by the Ministry of Health and listed on the Russian Vital and Essential Drugs List (ZHVNLP) — NOT FDA-approved and NOT EMA-approved. Research use only outside Russia.

View Details

Epitalon

≥98%

Synthetic Pineal Tetrapeptide (AEDG, Bioregulator Class — Mitochondrial / Longevity Research)

Synthetic tetrapeptide Ala-Glu-Asp-Gly (AEDG) modeled on the active fraction of the bovine pineal extract Epithalamin. In vitro telomerase findings were independently replicated in 2025; human data are limited to small single-center open-label observational studies from one research group. Research use only; not approved by FDA or EMA.

View Details